MedTrace Logo

Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes

NCT01622478 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2012-08-15

No results posted yet for this study

Summary

Sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) is currently debatable. It is possible that the tumor response to chemotherapy may alter the lymphatic drainage thus causing lower SLN identification rate and higher false negative rate. Further, the response of NAC can be different in each lymph nodes. It is doubtful whether SLNB can accurately predict axillary lymph node (ALN) status after NAC. The aim of this study to determine the identification rate, the false-negative rate, and the accuracy of SLNB after NAC for node positive breast cancer.

Conditions

Interventions

PROCEDURE

Sentinel lymph node biopsy

Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation

DRUG

Neoadjuvant chemotherapy

Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis

PROCEDURE

complete axillary lymph node dissection

Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy

PROCEDURE

positron emission tomography and ultrasonogram

Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy

Sponsors & Collaborators

  • Gangnam Severance Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-06-30
Completion
2009-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01622478 on ClinicalTrials.gov